Yahoo News: Cancer

Treatment for prostate cancer varies by area of U.S

Wed, 03/04/2015 - 21:58
By Kathryn Doyle (Reuters Health) - A new study of Medicare and private insurance claims confirms that treatment trends for localized prostate cancer differ by U.S. region, by state and even from county to county. “There are several treatment options for men with localized prostate cancer,” said lead author Dr. K. Clinton Cary of the urology department at Indiana University School of Medicine in ...

U.S. FDA approves Bristol-Myers immunotherapy for lung cancer

Wed, 03/04/2015 - 20:06
U.S. health regulators on Wednesday swiftly approved a Bristol-Myers Squibb Co drug that helps the immune system fight the most common form of lung cancer, sending the company's shares up more than 5 percent to a multi-year high. The eagerly anticipated Food and Drug Administration approval of the drug known as Opdivo came only about three months after Bristol provided trial results showing that ...

FDA approves Bristol-Myers drug for lung cancer

Wed, 03/04/2015 - 19:22
The Food and Drug Administration on Wednesday expanded approval of an innovative Bristol-Myers Squibb drug to treat the most common form of lung cancer. Regulators cleared Opdivo for patients with advanced ...

Bristol's $1 billion Bavarian deal may signal cancer vaccine revival

Wed, 03/04/2015 - 15:45
By Ben Hirschler LONDON (Reuters) - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's therapeutic prostate cancer vaccine Prostvac and signals that such shots may have a bright future when combined with so-called ...

Bavarian Nordic shares leap on $1 billion Bristol-Myers deal

Wed, 03/04/2015 - 09:00
Shares in Bavarian Nordic leapt as much as 39 percent on Wednesday after the Danish biotech company announced a prostate cancer drug deal with Bristol-Myers Squibb that could be worth at least $1 billion. The agreement gives the U.S. company an exclusive option to license and commercialize Bavarian's prostate cancer drug candidate Prostvac. Under the deal, Bavarian Nordic could receive up to ...

Cancer risk above 50 percent for Brits born in 1960

Tue, 03/03/2015 - 23:07
By Kathryn Doyle (Reuters Health) - More than half of people born after 1960 in the U.K. may be diagnosed with some form of cancer in their lifetimes, a new estimate suggests. “Everyone has to die of something and the longer people live the more likely that they will have previously been treated for a serious illness,” wrote Peter Sasieni, the study’s senior researcher from Queen Mary University ...

Tom Brokaw Writing Memoir About Battle With Cancer

Mon, 03/02/2015 - 21:40
The veteran NBC News anchor revealed a year ago that he had been diagnosed with multiple myeloma, which he said in December was in remission.

Want to Cut Your Cancer Risk? Lose That Weight (Op-Ed)

Mon, 03/02/2015 - 21:06
ASCO determined most people understand obesity is associated with a significantly elevated risk of heart disease, stroke and diabetes — but not cancer. During the past 20 years, there has been a dramatic increase in obesity nationwide, and rates remain stubbornly high. Researchers are exploring several hypotheses for how extra body fat can increase a person's cancer risk.

Amgen: Blood cancer drug Kyprolis beats rival's in study

Mon, 03/02/2015 - 18:19
Biotech drugmaker Amgen Inc.'s blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared with rival drug Velcade, according to the company. Kyprolis, an injected medicine ...

Brokaw memoir about his battle with cancer coming in May

Mon, 03/02/2015 - 16:51
Tom Brokaw is sharing the news about his battle with cancer, The former NBC anchor has a memoir coming out May 12, Random House announced Monday. The book is called "A Lucky Life Interrupted," ...

Brokaw memoir about his battle with cancer coming in May

Mon, 03/02/2015 - 15:12
NEW YORK (AP) — Tom Brokaw is sharing the news about his battle with cancer,

Terminal cancer care should do more to treat depression

Sun, 03/01/2015 - 17:21
By Janice Neumann (Reuters Health) - (Corrects in paragraphs 1 and 7 of Feb 26, 2015 story , that the doctors surveyed for the study were in The Netherlands, not Norway.) Depression could be clouding the last 24 hours of life for a significant number of people with advanced cancer, pointing to a need for better – and earlier - psychological help, according to a large study in The Netherlands ...

Younger men more bothered after prostate cancer treatment

Fri, 02/27/2015 - 22:04
By Shereen Lehman After treatment for localized prostate cancer, changes in quality of life will vary by age, as will men’s reactions to those changes, according to a new study. “While older and younger men start with different baseline quality of life function, older men may be less bothered by certain declines that may affect younger patients more,” Dr. Lindsay Hampson told Reuters Health in ...

Woman who stole, euthanized dog of man with cancer gets jail

Fri, 02/27/2015 - 21:15
PITTSBURGH (AP) — A woman who stole her cancer-stricken neighbor's dog and paid to have it euthanized was sentenced Friday to three to six months in jail.

Roche says EU agency recommends Avastin for cervical cancer

Fri, 02/27/2015 - 16:49
ZURICH (Reuters) - Roche said on Friday that European regulators had recommended approval of its drug Avastin in combination with chemotherapy as a treatment for women with an advanced form of cancer of the cervix. Avastin, which is already approved in Europe to treat advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer, was the Basel ...

Novartis lung cancer drug gets EU recommendation

Fri, 02/27/2015 - 12:31
European health regulators said on Friday they had recommended approval of a drug for advanced lung cancer developed by Swiss drugmaker Novartis that is intended to treat patients with a specific genetic mutation. It is designed for use in non-small cell lung cancer patients who have previously been treated with Pfizer's Xalkori, another ALK inhibitor. Between 2 and 7 percent of non-small cell ...

Terminal cancer care should do more to treat depression

Thu, 02/26/2015 - 16:20
By Janice Neumann Reuters Health - Depression could be clouding the last 24 hours of life for a significant number of people with advanced cancer, pointing to a need for better – and earlier - psychological help, according to a large study from Norway. Although it’s challenging to tease apart depression symptoms from the pain, fatigue and cognitive problems associated with end-stage cancer, more ...

Cancer-stricken Crowe promises to cheer on Black Caps

Thu, 02/26/2015 - 03:36
New Zealand great Martin Crowe has vowed not even life-threatening cancer will stop him from being among an expected capacity crowd at Auckland's Eden Park on Saturday to watch the Black Caps face Australia in an eagerly-anticipated World Cup clash. "For me, it will be the only (World Cup) game I get to, and it's almost like a bookend to my cricketing life, to be there on Saturday and watch ...

Bavarian Nordic vaccine helps prolong life in prostate cancer trial

Tue, 02/24/2015 - 19:42
An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute. Shares of Bavarian Nordic closed up almost 12 percent in Copenhagen after the company released the data on Tuesday. The study involved 30 ...

Novartis blood cancer drug wins U.S. OK after setback

Mon, 02/23/2015 - 21:59
(Reuters) - The U.S. Food and Drug Administration on Monday approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended against approval. The drug, Farydak, in clinical trials almost doubled to 10.6 months the amount of time it took for the disease to progress ...